| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Biotechnology sector is positive (overall 1.9, positive 4.5, negative -2.6) on 20251010. The forces of Sentiment towards Fundamentals (2.2), Sector Price Trend (1), Option Speculation (0.75), and Market Risk Prefrence (0.5) will drive up the price. The forces of Price Level (-0.5), Valuation Sentiment (-1), and Broad Market Trend (-1.1) will drive down the price. The total negative sentiment score -2.6 setups for a powerful pullback when all negative forces work together (the positive forces hibernate) triggered by negative news events or a overbought condition. The swing to upside will be significant considering the high positive sentiment forces (4.5). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Market Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-10 | 0% | 0.1% | 149.95 | 76 | -1.38% | 0.61% | 1 | 1.9 | 2.2 | 0 |
| 2025-10-09 | 1% | 0.1% | 152.05 | 91 | 0.04% | 0.88% | 2.2 | 5.7 | 2.9 | 4.3 |
| 2025-10-08 | 0% | 0% | 151.99 | 96 | 1% | 0.69% | 2.2 | 6.5 | 3.1 | 8 |
| 2025-10-07 | 0% | 0% | 150.48 | 94 | -0.03% | 0.55% | 2.4 | 5.7 | 2.8 | 0 |
| 2025-10-06 | 0% | 0% | 150.52 | 100 | -0.32% | 0.55% | 3.2 | 6.6 | 2.8 | 0 |
| 2025-10-05 | 0% | 0% | 3.5 | 6.9 | 2.8 | 0 | ||||
| 2025-10-04 | 0% | 0.1% | 3.5 | 7.1 | 3 | 0 | ||||
| 2025-10-03 | 0% | 0.1% | 151 | 114 | 0.92% | 0.56% | 3.5 | 7.3 | 3.2 | 0 |
| 2025-10-02 | 0% | 0.1% | 149.62 | 119 | 0.75% | 0.42% | 2.4 | 5.6 | 2.9 | 0 |
| 2025-10-01 | 0% | 0.1% | 148.51 | 130 | 2.87% | 0.49% | 3 | 3.6 | 3 | 0 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB Behaviors |
| ● Biotechnology (13%): The directional probability for IBB is 20% from last trading session on Thu. Oct 9, 2025. Both emotion level -1 is much lower than sentiment level 3.1 on Fri. Oct 10, 2025. Biotechnology (IBB) is attracting noticeable market attention on Fri. Oct 10, 2025. IBB is likely to move lower. When the price move is against the technical setup, sentiment and emotion, it's a sign of trend reversal. |
| 1 (8) Novo Nordisk to buy Akero for up to $5.2 billion as new CEO bets on liver drug candidate Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate. (https://www.cnbc.com/) Thu. Oct 9, 2025 | |
| 2 (-2) Novo Nordisk shares slip after pharma giant announces $4.7 billion U.S. acquisition Wegovy maker Novo Nordisk said Thursday it would acquire U.S. biotech firm Akero Therapeutics. (https://www.cnbc.com/) Thu. Oct 9, 2025 | |
| 3 (4) Novo Nordisk to buy Akero for up to $5.2 billion for promising liver drug STOCKHOLM (Reuters) -Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth. The deal underscores new Novo Nordisk CEO Mike Doustdar's efforts to revive sales growth and fend off intense competition from U.S. rival Eli Lilly. Doustdar, who took over the reins in July, last month also announced the company would cut 9,000 jobs. (https://finance.yahoo.com/) Thu. Oct 9, 2025 | |
| 4 (7) Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fatal liver disease. (https://www.marketwatch.com/) Thu. Oct 9, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA